---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-072531"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:53:12.922059+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Appoints Joel Jung as Interim CFO with $8k/month salary and 60k options

## Summary
- Interim CFO Joel Jung receives $8,000 monthly base salary under consulting agreement.
- Option grant of 60,000 ordinary shares; 1/4 vest Aug 28, 2024, rest monthly over 9 months.
- Exercise price equals closing price of ordinary shares on AIM on day before grant.
- Options fully vest upon change in control; agreement terminable with 3 months' notice.

## SEC filing metadata
- accession: 0000950170-24-072531
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/0000950170-24-072531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/rnlx-20240607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-072531
- JSON: https://secwatch.observer/filing/0000950170-24-072531.json
- Plain text: https://secwatch.observer/filing/0000950170-24-072531.txt

## Key facts
- Executive change
  Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/0000950170-24-072531-index.htm
- Executive change
  O. James Sterling resigned as Chief Financial Officer at Renalytix plc.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/0000950170-24-072531-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.